• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sanara MedTech Inc.

    10/8/24 5:36:55 PM ET
    $SMTI
    Industrial Specialties
    Health Care
    Get the next $SMTI alert in real time by email
    SC 13G 1 z108245sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    SANARA MEDTECH INC.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

      79957L100  
      (CUSIP Number)  
     
    09/30/24
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 7 
     

     

    CUSIP No.  79957L100
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Tall Pines Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a) ¨

    (b) x

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

         

    6

    SHARED VOTING POWER

     

    512,872

    7

    SOLE DISPOSITIVE POWER

     

         

    8

    SHARED DISPOSITIVE POWER

     

         

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    512,872

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     Page 2 of 7 
     

     

    CUSIP No.  79957L100
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Stonebridge Wealth Management, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a) ¨

    (b) x

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

         

    6

    SHARED VOTING POWER

     

    100,065

    7

    SOLE DISPOSITIVE POWER

     

         

    8

    SHARED DISPOSITIVE POWER

     

         

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    100,065

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.2%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

     

     Page 3 of 7 
     

     

    Item 1(a). Name of Issuer:
       
       Sanara Medtech, Inc
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       1200 Summit Ave, Suite 414, Fort Worth, Texas 76102
       
    Item 2(a). Name of Person Filing:
       
       Christopher M. Plahm
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       1010 Jorie Blvd., Suite 144 Oakbrook, IL 60523
       
    Item 2(c). Citizenship:
       
       USA
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, $0.001 par value
       
    Item 2(e). CUSIP Number:  79957L100

     

     Page 4 of 7 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 612,937   
       (b) Percent of Class: 7.2%
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote:         
          (ii) shared power to vote or to direct the vote: 612,937   
          (iii) sole power to dispose or to direct the disposition of:         
          (iv) shared power to dispose or to direct the disposition of:         

     

     Page 5 of 7 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

     Page 6 of 7 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: 10/07/2024  
       
       
      /s/ Christopher M Plahm  
      Name: Christopher M Plahm  
      Title: Investment Adviser  

     

     

    Page 7 of 7

     

     

     

    Get the next $SMTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMTI

    DatePrice TargetRatingAnalyst
    3/26/2025$50.00 → $51.00Buy
    H.C. Wainwright
    12/23/2024$50.00Buy
    H.C. Wainwright
    5/20/2022$45.00 → $40.00Overweight
    Cantor Fitzgerald
    6/30/2021$45.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ch. Acct. & Ch. Admin. Officer Mcneil Michael D. covered exercise/tax liability with 2,324 shares, decreasing direct ownership by 8% to 28,587 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    8/19/25 5:17:20 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Director Tanzberger Eric D was granted 3,590 shares, increasing direct ownership by 26% to 17,658 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    5/28/25 4:35:44 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Director Salamone Ann Beal was granted 2,809 shares, increasing direct ownership by 14% to 22,704 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    5/27/25 6:10:44 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Sanara MedTech with a new price target

    H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously

    3/26/25 7:42:25 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Smtek with a new price target

    H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00

    12/23/24 7:26:26 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Cantor Fitzgerald resumed coverage on Smtek with a new price target

    Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously

    5/20/22 9:07:28 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary  ●Net revenue increased 28% to

    8/13/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

    FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f

    7/15/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

    Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC ("THP"), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as

    7/14/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    SEC Filings

    View All

    SEC Form 10-Q filed by Sanara MedTech Inc.

    10-Q - Sanara MedTech Inc. (0000714256) (Filer)

    8/13/25 9:15:50 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    8/13/25 7:05:13 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    5/28/25 8:15:32 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Sanara MedTech Inc.

    SC 13G - Sanara MedTech Inc. (0000714256) (Subject)

    10/8/24 5:36:55 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Financials

    Live finance-specific insights

    View All

    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary  ●Net revenue increased 28% to

    8/13/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

    FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f

    7/15/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

    Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary  ●Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024.  ●Net loss of $3.5 million, compared to a net loss of $1.8 million in the first quar

    5/14/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments

    Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia

    1/21/25 4:08:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

    FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun

    4/5/24 9:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer

    FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch

    12/28/21 9:15:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care